TNFRSF1A antibody

Catalog No. ABIN2192207

There are 2+ publications for this product available. The Rat Monoclonal anti-TNFRSF1A antibody is suitable to detect TNFRSF1A in samples from Mouse. It has been validated for IP, FACS, IHC (fro) and IA.

Quick Overview for TNFRSF1A antibody (ABIN2192207)

Target: TNFRSF1A (Tumor Necrosis Factor Receptor Superfamily, Member 1A (TNFRSF1A))

Reactivity: Mouse

Host: Rat

Clonality: Monoclonal

Conjugate: This TNFRSF1A antibody is un-conjugated

Application: Immunoprecipitation (IP), Flow Cytometry (FACS), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunoassay (IA)

Clone: HM104

Product Details anti-TNFRSF1A Antibody

Sterility: 0.2 μm filtered

Application Details

Application Notes: It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one

Restrictions: For Research Use only

Handling

Buffer: PBS, containing 0.1 % bovine serum albumin and 0.02 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.

Expiry Date: 12 months

References for anti-TNFRSF1A antibody (ABIN2192207)

Ghezzi, Cerami: "Tumor necrosis factor as a pharmacological target." in: Methods in molecular medicine, Vol. 98, pp. 1-8, (2004) (PubMed).

Mennini, Bigini, Cagnotto, Carvelli, Di Nunno, Fumagalli, Tortarolo, Buurman, Ghezzi, Bendotti: "Glial activation and TNFR-I upregulation precedes motor dysfunction in the spinal cord of mnd mice." in: Cytokine, Vol. 25, Issue 3, pp. 127-35, (2003) (PubMed).

Target Details for TNFRSF1A

Target: TNFRSF1A (Tumor Necrosis Factor Receptor Superfamily, Member 1A (TNFRSF1A))

Background: The monoclonal antibody HM104 recognizes the extracellular part of the Tumor Necrosis Factor Receptor type I (TNF-RI) of the membrane-bound as well as the soluble receptor. TNF-RI (~55-60 kDa) is present on most cell types and is considered to play a prominent role in cell stimulation by TNF- alpha. TNF-alpha activates inflammatory responses, induces apoptosis, regulates cellular proliferation, and may even promote cancer progression. The effects of TNF-alpha are mediated by TNF-R1 and TNF-R2, which have both distinct and overlapping downstream signaling cascades. Induction of cytotoxicity and other functions are mediated largely via TNF-RI. TNF-R1 is equally well activated by both the 17 kDa soluble and 26 kDa membrane-bound form, whereas TNF-R2 is efficiently activated only by the membrane bound form of TNF-alpha. TNF-R1 signaling is initiated when trimeric TNF-alpha binds TNF-R1 receptors. Subsequent TNF-R1 trimerization promotes the recruitment of a proximal signaling complex composed of TNF Receptor Associated protein with a Death Domain (TRADD), Receptor Interacting Protein (RIP), cellular Inhibitor of Apoptosis Protein 1 (cIAP1), TNF Receptor Associated Factor 2 (TRAF2), and likely TRAF5. Studies with TNF-R1-deficient mice indicate that TNF-R1 mediates most of the proliferation, pro-inflammatory, and apoptosis-activating pathways. CD120a, Tumor necrosis factor receptor superfamily member 1A, p55/p60, TNFR-1 Aliases Rat IgG2a

Pathways: NF-kappaB Signaling, Apoptosis, Caspase Cascade in Apoptosis, Hepatitis C, Ubiquitin Proteasome Pathway